BridgeBio Pharma Inc. (NASDAQ: BBIO) reported that its drug acoramidis demonstrated a 44.7% reduction in all-cause mortality and a 49.3% reduction in cardiovascular mortality in patients with transthyretin amyloid cardiomyopathy through 54 months of treatment.

The data from the ATTRibute-CM open-label extension trial showed continuous acoramidis treatment achieved statistically significant mortality reductions compared to patients who switched from placebo to acoramidis (p<0.0001 for both measures). The results were presented at the American College of Cardiology Annual Scientific Sessions and published simultaneously in JAMA Cardiology.

The trial also found that acoramidis mitigated increases in NT-proBNP, a biomarker for heart failure, and maintained quality of life scores as measured by the Kansas City Cardiomyopathy Questionnaire through 54 months. The drug continued to be well tolerated with no new long-term safety concerns identified.

"The ATTRibute-CM long-term data show that early and continuous treatment with acoramidis can meaningfully change the trajectory of this disease," said Dr. Prem Soman of University of Pittsburgh School of Medicine, who presented the findings.

Acoramidis is approved as Attruby in the United States and as BEYONTTRA in Europe for treating the cardiomyopathy associated with transthyretin-mediated amyloidosis. The drug is described as a selective small molecule that achieves near-complete transthyretin stabilization of 90% or greater.

The company also presented three additional poster presentations at the cardiology conference examining various aspects of acoramidis treatment and real-world treatment patterns for the condition.